Quarterly Period Covered: Q1 of fiscal year 2027 (April 1 - June 30, 2026), filed August 5, 2026 Company Overview: McKESSON CORP is a wholesale drug distributor (SIC 5122) headquartered in Irving, Texas with fiscal year ending March 31 Financial Statements Included: The filing contains unaudited consolidated financial statements for the quarter ended June 30, 2026, with comparative periods from…

Our analysis rates this filing BEARISH. McKesson faces a HIGH concern level (7.0/10) driven by multiple material headwinds converging in the near term. The combination of an opioid litigation overhang (severity 8), active workforce restructuring with uncertain costs (severity 7), structural margin…

Concern level: HIGH (7.0/10). Key factors: Two high-severity risks identified: Opioid litigation (severity 8) and workforce restructuring (severity 7) with material near-term cash flow impact; Risk trend is INCREASING overall with riskScore of 7.1, indicating deteriorating risk profile; Workforce and Operating Model Optimization restructuring plan in active execution phase with quantified but…

Notable risk changes: Workforce restructuring plan now in active execution phase with quantified cost ranges, indicating material near-term earnings headwinds and cash outflows; Norway operations divested during FY2026, signaling strategic portfolio rationalization and potential write-downs from underperforming assets; Two significant acquisitions (PRISM Vision Holdings and Core Ventures) completed in Q1 FY2027,…

The model predicts MCK will underperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.